Stay updated with breaking news from Access Consortium. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Manufacturers will not need to conduct whole new clinical trials when they adapt their vaccines for newer coronavirus strains
Why governments need to rethink their regulatory framework in 2021 - Magazine Article - PharmaTimes
UK was ill-prepared for the transition of regulation from the EU and still does not have the infrastructure in place to manage new trade relationships UK...
UK COVID-19 vaccines delivery plan Updated 13 January 2021 © Crown copyright 2021 This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. This publication is available at https://www.g...
In the fall of 2016, Alnylam Pharmaceuticals was looking to expand. The Cambridge, Massachusetts–based company had therapies based on RNA interference (RNAi) technology in late-stage clinical testing for a handful of rare diseases, and wanted to establish a presence in Europe to better serve patients there. By the end of the following year, the company had opened offices in Maidenhead, UK; Zug, Switzerland; and Amsterdam, the Netherlands, to serve as its three European hubs. Scouting for new locations in Europe, the company found Amsterdam particularly appealing, says Marco Fossatelli, Alny...